Source link : https://www.newshealth.biz/health-news/dont-call-it-cancer-clues-to-exceptional-responses-more-predictions-for-2025/
More debate about whether the lowest-risk prostate cancers should even be called “cancer.” (Harvard Health Publishing) Four cancer drugs — palbociclib (Ibrance), enzalutamide (Xtandi), pomalidomide (Pomalyst), and acalabrutinib (Calquence) — were selected by the Biden administration for the next round of Medicare drug price negotiation. Atara Biotherapeutics acknowledged receipt of a complete response letter from […]
Author : News Health
Publish date : 2025-01-17 19:29:28
Copyright for syndicated content belongs to the linked Source.
inHealth